Integrated Programs: Early Development
Simplify early development and accelerate to Proof-of Concept Proof-of-Concept (POC) is a key milestone in the development of a new drug candidate. At Quotient Sciences, we understand the increasing pressures on R&D budgets, therefore the need to transition molecules through early development to POC needs to be fast and cost-effective.
CureSearch Pediatric Early Development Symposium
Join Nazim Kanji as he presents at the CureSearch Pediatric Early Development Symposium from 1st-2nd October 2020
Application of Translational Pharmaceutics® to reduce time, cost and risk in the early development of inhaled drug products - RDD
The efficiency and effectiveness of new drug development has remained problematic over the last decade. Translational Pharmaceutics has emerged as a new paradigm to improve R&D productivity.
How can you conserve cash and still accelerate to your key early development milestones?
This webinar will explore some of the challenges faced by industry today and discuss how early drug development timelines can be accelerated, whilst at the same time conserving cash flow.
Accelerating molecules through to Proof-of-Concept, with an integrated early development program
This webinar highlights how a fully integrated development plan can bring together the needs of the drug product team and the clinical development team.
Accelerating drug product development from early phase to scale up and commercialisation
This webinar covers a real-world case study with Druggability Technologies, a specialty pharmaceutical company, which utilized Quotient’s integrated approach to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib, using proprietary super-API compositions developed by DRGT.
The Role of Biopharmaceutics in Early Drug Development
This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan.
Adaptive manufacturing: a new paradigm to improve efficiency and effectiveness in early oncology development - AAPS 2014
There is an unmet need in the industry for a more efficient and flexible approach to provide drug product for early clinical studies. Presented here is an innovate approach to overcome these challenges by utilising a real-time, adaptive manufacturing and supply platform.
14C Microtracer approaches to inform formulation development strategies in early clinical drug development - AAPS 2016
This poster describes how combining an intravenous (IV) microtracer regimen with an oral tracer regimen, can generate key pharmacokinetic (PK) parameters.
Integrated Early-Stage Drug Development and Manufacturing: Accelerating Molecules to Proof-of-Concept
This webinar highlights how by breaking down the barriers between traditional outsourcing channels and workflows, drug development activities and key functional groups including formulation development, manufacturing and clinical research can be much more closely integrated to accelerate early-stage drug development, reduce overall expenditure and shorten time to proof of concept.
Real-time drug product manufacturing to enable accelerated early clinical development of spray dried dispersion based formulations - AAPS 2017
This poster describes how adopting a real-time drug product manufacturing approach allowed initiation of the FIH study within 12 weeks of initiating SDD process transfer.
Flow Chemistry for Accelerated Drug Substance Delivery
This webinar discusses drug substance manufacturing in early development and the very concept of being fast, agile and innovative.
When you are looking for a partner who is dedicated to Phase I trials and early development, rely on Quotient Sciences. We accelerate your molecule from first-in-human to proof-of-concept, helping you make critical decisions earlier.
Developing spray dried dispersions for early phase clinical trials and beyond
Formulation strategies and the DevelopabilityClassification System (DCS). Benefits of spray-drying to address poor drug solubility. Fit-for-purpose systems in early clinical research and effectively transitioning to solid oral dosage forms. Adaptive clinical manufacturing “tailored” to the clinical study and patient recruitment.
First-in-Human to Proof-Of-Concept: Addressing Development Challenges and Accelerating Timelines
Increasing pressure on R&D budgets means the design, speed and precision of early phase clinical programs is critical for success.
10th American DDF Summit
Discuss your drug development requirements with us at the 10th American Drug Delivery and Formulation event on December 14 & 15
Leveraging Bioanalysis to Accelerate Drug Development Programs: Challenges and Considerations
Join Quotient’s Vice President of Bioanalysis, Dr Stuart McDougall, as he discusses how best to leverage bioanalysis within drug development programs to accelerate timelines & enhance the likelihood of clinical & commercial success.
Accelerating Peptide Development: Strategies to optimize the formulation and manufacture of peptide therapeutics
This webinar reviews the challenges when developing a peptide formulation, investigates the best route of delivery for your molecule, alongside looking into formulation strategies and manufacturing considerations, before exploring options for an integrated approach to accelerate peptide development.
Accelerating Peptide Development Webinar Series
Register today for our Peptide Development webinar series taking place on July 15th, 20th & 22nd, entitled- Accelerating Peptide Development: Strategies to optimize the formulation & manufacture of peptide therapeutics
Peptide Development Webinar - July 20th
Register today for our upcoming Peptide Development webinar taking place on July 20th, entitled- Accelerating Peptide Development: Strategies to optimize the formulation & manufacture of peptide therapeutics
Peptide Development Webinar - July 22nd
Register today for our upcoming Peptide Development webinar taking place on Thursday, July 22nd, entitled- Accelerating Peptide Development: Strategies to optimize the formulation & manufacture of peptide therapeutics
Peptide Development Webinar - July 15th
Register today for our upcoming Peptide Development webinar taking place on Thursday, July 15th, entitled- Accelerating Peptide Development: Strategies to optimize the formulation & manufacture of peptide therapeutics
From candidate selection through to proof-of-concept
Building a robust understanding of your API characteristics matched against your development programme goals, supports the efficient transition of drug products from candidate selection through to proof-of-concept. Starting @ 4pm (BST-UK), 11pm (ET), 8am (PT) and 6pm (BST-UK), 1pm (ET), 10am (PT)
Quotient will be attending CPhI Worldwide 2021 from November 9-11, 2021.
Drug Product Strategies to Accelerate from Candidate Selection to Proof-of-Concept
This webinar will summarise how a fully integrated development plan can bring together the needs of the drug product team and the clinical development team.
Development of a Modified Release Tablet Containing an API Prone to Form Changes and Gelling in Aqueous Media
Development of an MR formulation of Cmp-1 was planned using RapidFACT®: an integrated approach that allows formulation optimization based on human PK data with an adaptive clinical design. Selection of a discriminatory in vitro dissolution test was an important early development activity.
JPAG Stability Symposium
Quotient Sciences' will be attending the JPAG Stability Symposium on June 30, 2022.
Translational Pharmaceutics and the Benefits of Real-Time Adaptive Manufacturing
This webinar explains the benefits of Translational Pharmaceutics, a unique approach which integrates formulation development, real-time adaptive GMP manufacturing and clinical research. It will illustrate how, by breaking down the siloes and integrating horizontally, we can operate with more flexibility in the early phases of drug development, reducing costs and shortening timelines.
AAPS 2020 Poster - A Quality by Deisgn Approach to Optimize and Accelerate Formulation and Process Development Leading towards Registration Batches Manufacturing
To improve the existing formulation composition and manufacturing process of compound X which was designed for early phase development Process optimization activities focused on improving the flow characteristics of the granules, minimizing or eliminating segregation and increasing the manufacturing yield with the aim of achieving a robust process prior to the product registration campaign.
Determining drug exposure is vital for the assessment of drug safety and efficacy. Quotient's Bioanalytical team, develop and refine methods so exposure can be assessed reliably and accurately in a variety of biological matrices.
Bioanalytical services to accelerate drug development
Delivering rapid bioanalytical data is critical to drug development. From drug discovery, through to preclinical and clinical studies, understanding drug exposure and behavior are imperative to dose selection, and accelerating drugs to clinic and commercialization. Through the use of robust bioanalytical techniques, biological samples can be processed and analyzed to identify and quantify compounds of interest, such as small molecules and their metabolites, as well as peptides, proteins, nucleic acids and other analytes.
Solubility Webinar October 26th
Register today for our solubility focused webinar on October 26th.
Solubility Webinar Series
Register today for our solubility focused webinar series taking place on October 21st, 26th, or 28th for our Solubility focused webinar entitled: Accelerated development strategies for poorly soluble molecules
Solubility Webinar October 21st
Register today for our solubility focused webinar on October 21st.
Solubility Webinar October 28th
Register today for our upcoming solubility focused webinar on October 28th.
Solubilizing the insoluble - Royal Society of Chemistry Event
Join Quotient at the virtual Solubilizing the insoluble - Formulation approaches event on December 2, 2021
Formulation strategies for poorly soluble molecules - Pharmaceutics and biopharmaceutics considerations
This presentation uses expert insight and case studies to explore formulation and solubility challenges and discuss the best strategies and technologies for advancing poorly soluble molecules, to deliver success.
BioPharm America 2020 Virtual Partnering Conference
Schedule a partnering meeting with our CSO, Peter Scholes at BioPharm America to discuss you drug development needs.
Clinical Trial Manufacturing
Understanding that early phase clinical testing is a pivotal milestone in the development of your drug product, Quotient Sciences offers clinical trial manufacturing, testing and certification services designed to meet your individual requirements.
Maximising Formulation Flexibility in First-in-Human Trials
This edition of OBN’s Digital Event series is being organized in collaboration with Quotient Sciences and will highlight how a fully integrated development plan can bring together the needs of the drug product team and the clinical development team.
Enhanced formulation decision-making in early phase clinical trials for parenteral products
This presentation describes the principles and applications of Translational Pharmaceutics: an R&D platform integrating formulation development, real-time adaptive GMP manufacturing and clinical testing in order to accelerate drug development cycles.
AAPS 2019 Poster- Applications and Benefits of Healthy Volunteer Trials to Accelerate Oncology Drug Development
Presented at AAPS 2019: Phase I drug development for oncology compounds is traditionally conducted directly in patient populations. Oncology molecules have historically been cytotoxic, meaning their safety and risk:benefit profile makes them unviable for dosing in healthy subjects. While this ensures reduced nonclinical requirements, rapid access to patient data and an earlier assessment of efficacious potential, it can also present challenges. For example, patients recruited in Phase I trials typically are at end of life care and will be taking multiple co-medications and have multiple co-morbidities (e.g. liver and kidney function may vary greatly among the recruited subjects). Practically, recruiting patients into Phase I studies can also be problematic, requiring multiple clinical sites and protracted recruitment times for what would traditionally be single site, quickly recruited healthy volunteer studies.
Considerations for First-In-Human Clinical Trials: Planning for Success
The First-in-human (FIH) clinical trial is a pivotal milestone in the drug development process and is the stage-gate before molecules can proceed to Phase II/proof of concept trials.